| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Uproleselan | GMI-1271; APL-106 | Phase 3 Clinical | Crescent Biopharma Inc | Coronavirus Disease 2019 (COVID-19); Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Venous Thrombosis | Details |
| E-selectin targeting humanized antibody (LifeArc) | Phase 1 Clinical | Lifearc | Respiratory Distress Syndrome, Adult; Sepsis | Details | |
| GMI-1687 | GMI-1687; APL-108 | Phase 1 Clinical | Crescent Biopharma Inc | Anemia, Sickle Cell; Inflammation; Leukemia, Myeloid, Acute | Details |
| PF-07209326 | PF-07209326 | Phase 1 Clinical | Pfizer Inc | Anemia, Sickle Cell | Details |